CDKL5

Cyclin-dependent kinase-like 5 · O76039 · CDKL5 on Sugi Atlas →

8,887 patent compounds predicted against CDKL5, 7,612 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Riviciclib (SCHEMBL290347)	1.00	2/20
Riviciclib (SCHEMBL663219)	1.00	2/20
Riviciclib (SCHEMBL663220)	1.00	2/20
Riviciclib (SCHEMBL290572)	0.98	2/20
Riviciclib (SCHEMBL291157)	0.98	2/20
Riviciclib (SCHEMBL665748)	0.98	2/20
Riviciclib (SCHEMBL665749)	0.98	2/20
Alvocidib (SCHEMBL1170833)	0.98	2/20
SCHEMBL1179589	0.84	2/20
SCHEMBL1179591	0.84	2/20
SCHEMBL1180321	0.84	2/20
SCHEMBL1180324	0.84	2/20
Hydrochloric Acid (SCHEMBL1180100)	0.82	2/20
Hydrochloric Acid (SCHEMBL1180102)	0.82	2/20
Hydrochloric Acid (SCHEMBL1180106)	0.82	2/20
SCHEMBL1180211	0.81	2/20
SCHEMBL1180213	0.81	2/20
SCHEMBL1180222	0.81	2/20
Hydrochloric Acid (SCHEMBL1179466)	0.80	2/20
Hydrochloric Acid (SCHEMBL1179467)	0.80	2/20

Clinical trials — most relevant to CDKL5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)	PHASE3	COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	COMPLETED
Abemaciclib + Pembrolizumab In Glioblastoma	PHASE2	WITHDRAWN
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
Avelumab, Palbociclib and Axitinib in Advanced RCC	PHASE2	WITHDRAWN
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy	PHASE2	COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy	PHASE2	COMPLETED
Palbociclib With Everolimus + Exemestane In BC	PHASE1/PHASE2	COMPLETED
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors	PHASE2	WITHDRAWN
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma	PHASE1	COMPLETED
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers	PHASE1	COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
Study of FCN-437c in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
The Association Between Fever and CDKL5 Deficiency Disorder: a Nationwide Survey	nan	COMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN
The SONImage Study	nan	ACTIVE_NOT_RECRUITING
Implementing Patients´ Competence in Oral Breast Cancer Therapy	nan	UNKNOWN
Genetic Analysis of Familial Melanoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CDKL5 binder may also engage these)

Protein	Name	Similarity
Q3UTQ8	—	1.000	Q3UTQ8 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.999	landscape →
CILK1	Serine/threonine-protein kinase ICK	0.999	landscape →
A6QP06	—	0.998	A6QP06 →
A7MBB4	—	0.998	A7MBB4 →
BMP2K	BMP-2-inducible protein kinase	0.998	landscape →
Q2PFD7	—	0.998	Q2PFD7 →
P46200	—	0.997	P46200 →
Q9JKV2	—	0.997	Q9JKV2 →
Q5R8X7	—	0.997	Q5R8X7 →
A0A1L8HFX9	—	0.997	A0A1L8HFX9 →
Q3MJK5	—	0.997	Q3MJK5 →
P10244	—	0.997	P10244 →
B2GUY1	—	0.997	B2GUY1 →
Q14AX6	—	0.997	Q14AX6 →
A2RUV4	—	0.996	A2RUV4 →
Q8VII8	—	0.996	Q8VII8 →
Q3YC04	—	0.996	Q3YC04 →
Q0WPH8	—	0.996	Q0WPH8 →
CCNT1	Cyclin-T1	0.996	landscape →
Q4JM28	—	0.995	Q4JM28 →
Q6DFV3	—	0.995	Q6DFV3 →
P22199	—	0.995	P22199 →
Q1HKZ5	—	0.995	Q1HKZ5 →
Q80TZ9	—	0.995	Q80TZ9 →
Q9QWV9	—	0.995	Q9QWV9 →
Q9R1Z8	—	0.995	Q9R1Z8 →
Q9HCH5	—	0.995	Q9HCH5 →
Q9P1A6	—	0.995	Q9P1A6 →
Q86TC9	—	0.995	Q86TC9 →